<?xml version="1.0" encoding="UTF-8"?>
 <!-- An example STUDY with all the required fields -->
<studies>
    <study>
        <shortTitle>Ph 4, DB, MC, Rand, Cross-over study to compare Multihance vs Omniscan in MRI of
            the brain</shortTitle>
        <longTitle>Phase IV, Double-Blind, Multi-Center, Randomized, Cross-Over Study to Compare
            0.10 mmol/kg of Multihance with 0.10 mmol/kg of Omniscan in Magnetic Resonance Imaging
            (MRI) of the Brain</longTitle>
        <phaseCode>Phase I Trial</phaseCode>
        <ctcVersion><name>2</name></ctcVersion>
        <identifiers>
            <identifier>
                <type>Site Identifier</type>
                <value>99B061aa</value>
                <source>Wake Forest Comprehensive Cancer Center</source>
                <primaryIndicator>false</primaryIndicator>
            </identifier>

            <identifier>
                <type>Protocol Authority Identifier</type>
                <value>99B063bb</value>
                <source>National Cancer Institute</source>
                <primaryIndicator>true</primaryIndicator>
            </identifier>
            
        </identifiers>
        
        <studyOrganizations>
            <studyFundingSponsor>
                <organization>
                    <name>default</name>
                </organization>
            </studyFundingSponsor>
            <studySite>
                <organization>
                    <name>default</name>
                </organization>
            </studySite>
            <studySite>
                <organization>
                    <name>default</name>
                </organization>
            </studySite>
        </studyOrganizations>
    </study>
   
    <study>
        <shortTitle>Ext Study Eval the long-term safety of ICA-17043 w/ or w/out hydroxyurea in subjects w/sickle-cell d</shortTitle>
        <longTitle>An Open-Label Extension Study Evaluating the Long-Term Safety of ICA-17043 with or without Hydroxyurea Therapy in Subjects with Sickle-Cell Disease</longTitle>
        <description>Hematologic,IND_HEMONC</description>
        <phaseCode>Phase I Trial</phaseCode>
        <ctcVersion><name>2</name></ctcVersion>
        
        <identifiers>
            <identifier>
                <type>Site Identifier</type>
                <value>99B061cc</value>
                <source>Wake Forest Comprehensive Cancer Center</source>
                <primaryIndicator>false</primaryIndicator>
            </identifier>
            
            <identifier>
                <type>Protocol Authority Identifier</type>
                <value>99B063dd</value>
                <source>National Cancer Institute</source>
                <primaryIndicator>true</primaryIndicator>
            </identifier>
            
        </identifiers>
        
        <studyOrganizations>
            <studyFundingSponsor>
                <organization>
                    <name>default</name>
                </organization>
            </studyFundingSponsor>
            <studySite>
                <organization>
                    <name>default</name>
                </organization>
            </studySite>
            <studySite>
                <organization>
                    <name>default</name>
                </organization>
            </studySite>
        </studyOrganizations>
       
    </study>
    
    <study>
        <shortTitle>Rand Ph 2 trial of rit vs lenal vs rit+lenal in rec follicular NHL after relapse from a rit-containi</shortTitle>
        <longTitle>A Randomized Phase II Trial of Rituximab vs Lenalidomide vs Rituximab + Lenalidomide in Recurrent Follicular Non-Hodgkin Lymphoma (NHL) After Relapse from a Rituximab-Containing Combination Regimen</longTitle>
        <description>Non-Hodgkins Lymphoma,CALGB</description>
        <phaseCode>Phase II Trial</phaseCode>
        <ctcVersion><name>3</name></ctcVersion>
        
        <identifiers>
            <identifier>
                <type>Site Identifier</type>
                <value>99B061ee</value>
                <source>Wake Forest Comprehensive Cancer Center</source>
                <primaryIndicator>false</primaryIndicator>
            </identifier>
            
            <identifier>
                <type>Protocol Authority Identifier</type>
                <value>99B063ff</value>
                <source>National Cancer Institute</source>
                <primaryIndicator>true</primaryIndicator>
            </identifier>
            
        </identifiers>
        
        <studyOrganizations>
            <studyFundingSponsor>
                <organization>
                    <name>default</name>
                </organization>
            </studyFundingSponsor>
            <studySite>
                <organization>
                    <name>default</name>
                </organization>
            </studySite>
            <studySite>
                <organization>
                    <name>default</name>
                </organization>
            </studySite>
        </studyOrganizations>
    </study>
    
    <study>
        <shortTitle>Rand, DB, Plac-Cont trial to eval palifermin in the red of acute graft vs host dx in sub w/hem malig</shortTitle>
        <longTitle>A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate Palifermin (rHuKGF) in the Reduction of Acute Graft Versus Host Disease in Subjects with Hematologic Malignancies Undergoing Allogeneic Marrow/PBPC Transplantation</longTitle>      
        <description>Hematologic,IND_HEMONC</description>
        <phaseCode>Phase II Trial</phaseCode>
        <ctcVersion><name>3</name></ctcVersion>
        
        <identifiers>
            <identifier>
                <type>Site Identifier</type>
                <value>99B061gg</value>
                <source>Wake Forest Comprehensive Cancer Center</source>
                <primaryIndicator>false</primaryIndicator>
            </identifier>
            
            <identifier>
                <type>Protocol Authority Identifier</type>
                <value>99B063hh</value>
                <source>National Cancer Institute</source>
                <primaryIndicator>true</primaryIndicator>
            </identifier>
            
        </identifiers>
        
        <studyOrganizations>
            <studyFundingSponsor>
                <organization>
                    <name>default</name>
                </organization>
            </studyFundingSponsor>
            <studySite>
                <organization>
                    <name>default</name>
                </organization>
            </studySite>
            <studySite>
                <organization>
                    <name>default</name>
                </organization>
            </studySite>
        </studyOrganizations>
        
    </study>
    
    
    <study>
        <shortTitle>Ph 2 study of maint therapy w/decitabine following stan ind and cytogenetic risk-adapted intensificati</shortTitle>
        <longTitle>Phase II Study of Maintenance Therapy with Decitabine Following Standard Induction and Cytogenetic Risk-Adapted Intensification in Previously Untreated Patients with AML less than 60 Years</longTitle>        <description>Hematologic,IND_HEMONC</description>
        <phaseCode>Phase II Trial</phaseCode>
        <ctcVersion><name>2</name></ctcVersion>
        
        <identifiers>
            <identifier>
                <type>Site Identifier</type>
                <value>99B061ii</value>
                <source>Wake Forest Comprehensive Cancer Center</source>
                <primaryIndicator>false</primaryIndicator>
            </identifier>
            
            <identifier>
                <type>Protocol Authority Identifier</type>
                <value>99B063jj</value>
                <source>National Cancer Institute</source>
                <primaryIndicator>true</primaryIndicator>
            </identifier>
            
        </identifiers>
        
        <studyOrganizations>
            <studyFundingSponsor>
                <organization>
                    <name>default</name>
                </organization>
            </studyFundingSponsor>
            <studySite>
                <organization>
                    <name>default</name>
                </organization>
            </studySite>
            <studySite>
                <organization>
                    <name>default</name>
                </organization>
            </studySite>
        </studyOrganizations>
        
    </study>
    
   
</studies>